GB202011284D0 - Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients - Google Patents

Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Info

Publication number
GB202011284D0
GB202011284D0 GBGB2011284.3A GB202011284A GB202011284D0 GB 202011284 D0 GB202011284 D0 GB 202011284D0 GB 202011284 A GB202011284 A GB 202011284A GB 202011284 D0 GB202011284 D0 GB 202011284D0
Authority
GB
United Kingdom
Prior art keywords
cov
sars
beta
infected patients
improve outcome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2011284.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synairgen Research Ltd
Original Assignee
Synairgen Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synairgen Research Ltd filed Critical Synairgen Research Ltd
Priority to GBGB2011284.3A priority Critical patent/GB202011284D0/en
Publication of GB202011284D0 publication Critical patent/GB202011284D0/en
Priority to EP21749262.8A priority patent/EP4181944A1/en
Priority to PCT/GB2021/051853 priority patent/WO2022018422A1/en
Priority to JP2023504184A priority patent/JP2023535710A/en
Priority to KR1020237005777A priority patent/KR20230041097A/en
Priority to US18/016,964 priority patent/US20230338475A1/en
Ceased legal-status Critical Current

Links

GBGB2011284.3A 2020-07-20 2020-07-21 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients Ceased GB202011284D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB2011284.3A GB202011284D0 (en) 2020-07-21 2020-07-21 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
EP21749262.8A EP4181944A1 (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
PCT/GB2021/051853 WO2022018422A1 (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
JP2023504184A JP2023535710A (en) 2020-07-20 2021-07-19 Inhaled interferon-beta to improve outcomes in patients infected with SARS-CoV-2
KR1020237005777A KR20230041097A (en) 2020-07-20 2021-07-19 Inhaled interferon-beta to improve outcomes in patients with SARS-CoV-2 infection
US18/016,964 US20230338475A1 (en) 2020-07-20 2021-07-19 USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2011284.3A GB202011284D0 (en) 2020-07-21 2020-07-21 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Publications (1)

Publication Number Publication Date
GB202011284D0 true GB202011284D0 (en) 2020-09-02

Family

ID=72338954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2011284.3A Ceased GB202011284D0 (en) 2020-07-20 2020-07-21 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Country Status (1)

Country Link
GB (1) GB202011284D0 (en)

Similar Documents

Publication Publication Date Title
IL239488A0 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
GEP20166455B (en) Methods of administering pirfenidone therapy
IN2012DN06616A (en)
MY173215A (en) Acetylcysteine compositions and methods of use thereof
NZ599246A (en) Pirfenidone therapy and inducers of cytochrome p450
MX2021012272A (en) Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes.
NZ599511A (en) Recombinant human cc10 protein for treatment of influenza
EP4112050A4 (en) Use of nucleoside compound in treatment of coronavirus infectious diseases
MX2015004009A (en) Glycosidase regimen for treatment of infectious disease.
BR112014007580A2 (en) medical intervention device and method of manufacture
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
IL308992A (en) Treatment of cancer in patients with soluble fr-alpha
GB202106014D0 (en) Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB202011284D0 (en) Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB202011216D0 (en) Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients
MX2022007908A (en) Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv.
MX2019002657A (en) Combinations with a backbone-cyclized peptide.
MX2019002894A (en) Combinations with a backbone-cyclized peptide.
RU2013129824A (en) NEW TREATMENT OF HEPATITIS C VIRUS INFECTION
MX2023001301A (en) Antiviral use of liraglutide and gefitinib.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
GB202100322D0 (en) Artificial up-regulation of EGR1 protein in COVID19 infected lung tissues as a therapeutic treatment
RU2012114097A (en) THERAPEUTIC AGENT AGAINST CHRONIC PAIN
GB202403191D0 (en) Medicament and medicament combination for use in the treatment of infectious disease
ZA202201362B (en) Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumor

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)